



Health and  
Environmental  
Sciences  
Institute

# 2018 Sponsorship Application

## Sponsorship Information

Sponsorship in the ILSI Health and Environmental Sciences Institute (HESI) is open to business entities that are producers of pharmaceuticals, cosmetics, agricultural and other industrial chemicals, paper products, personal care and household products, food and beverages, communications products, transportation products, or energy products, or of ingredients or containers used in, or in connection with these products. Providers of scientific and technical services used in the safety testing or production of these products or in the assessment of the human health and environmental safety of these products are also eligible. Sponsorship dues are based on annual worldwide sales of the joining organization. Individuals and trade associations are not eligible for HESI sponsorship.

Application Date:

Company Name:

Street Address:

Street Address 2:

City:  State:  Postal Code:

Country:

Phone:  Fax:

Company Web Address:

## Indicate Type of Company

- Agricultural Chemical     Beverages     Biotechnology     Communication Products     Chemical
- Cosmetics     Energy Products     Food     Forestry     Paper Products     Personal Care
- Petrochemical     Pharmaceutical     Technical Service Provider     Transportation Products

Other:

## Sponsorship Fees and Committee Assessments

HESI's annual corporate sponsorship fees are based on sponsors' worldwide sales using the most recently available year-end figures. Annual dues for sponsorship are determined by the HESI Board of Trustees. Your company's sponsorship dues will be calculated by HESI in accordance with the schedule below, and invoiced accordingly. Separate assessments are made for committee sponsorships and support of their activities; such assessments are determined by the committee sponsors themselves.

*HESI is a 501(c)(3) scientific organization; therefore, HESI sponsorship fees in the United States are 100% tax deductible.*

**2017 Worldwide Sales (in US Dollars):**

(If 2017 worldwide sales are not available, please use 2016 worldwide sales.)

## Sponsorship Fee Schedule in US Dollars

<u>Worldwide Sales</u>	<u>Base Fee</u>
Less than \$5 Million dollars	\$800
\$5 Million to \$49.99 Million	\$3,000
\$50 million to \$499 million	\$5,400
\$500 million to \$999 million	\$10,800
\$1 billion to 1.99 billion	\$16,200 + (\$5,400 * _____ billion over 1 billion)
\$2 billion to 4.99 billion	\$21,600 + (\$1,800 * _____ billion over 2 billion)
\$5 billion to 9.99 billion	\$27,000 + (\$860 * _____ billion over 5 billion)
\$10 billion to 19.99 billion	\$31,300 + (\$290 * _____ billion over 10 billion)
\$20 billion to 29.99 billion	\$34,200 + (\$490 * _____ billion over 20 billion)
\$30 billion to 39.99 billion	\$39,100 + (\$490 * _____ billion over 30 billion)
\$40 billion to 99.999 billion	\$44,000 + (\$102 * _____ billion over 40 billion)
\$100 billion and above	\$50,100

## Committee and Project Interests

Please check the following committees and/or projects of interest that your company would like to join. Mission statements for each committee and project can be found on pages 5 and 6 of this application.

### TECHNICAL COMMITTEES:

- Application of Genomics to Mechanism-Based Risk Assessment - \$10,000
- Animal Alternatives in Environmental Risk Assessment - \$15,000
- Biomarkers of Nephrotoxicity - \$3,000
- Development of Methods for a Tiered Approach to Assess the Bioaccumulation of Chemicals - \$15,000
- Cardiac Safety - \$7,000
- Cell Therapy - TRacking, Circulation, & Safety (CT-TRACS) - \$8,000
- Developmental and Reproductive Toxicology - \$10,000
- Framework for Intelligent Non-Animal Alternative Methods for Safety Assessment - \$7,000

- Genetic Toxicology - \$10,000
- Immunotoxicology - \$10,000
- PBPK Project – \$10,000
- Protein Allergenicity - \$40,000
  - COMPARE Allergen Database - \$30,000
- Risk Assessment in the 21st Century - \$20,000
- Translational Biomarkers of Neurotoxicity – \$7,000

### EMERGING ISSUES (EI) SUBCOMMITTEES:

Subcommittees are identified through the annual EI process upon the recommendation of the EI Steering Committee and approval of the HESI Board of Trustees. New subcommittees receive full HESI financial support for the first year. During the second year, subcommittees are funded through sponsor assessments with limited matching funds from HESI.

- Development of a Tiered Approach for UVCB Ecological Risk Assessment
- Microbiome Biomarkers of Disease and Toxicity- \$6,000

## Company Representation

Your company's official representative to HESI will receive all sponsor mailings, will serve as the voting representative within the HESI Assembly, and will be listed as your company's primary contact in the ILSI Membership Directory. If you wish to add the name(s) of other company personnel to the HESI mailing list to receive general mailings and to be listed in the ILSI Membership Directory, please enter the additional name(s) and full contact information as indicated below.

### Official Representative

First Name:  MI:  Last Name:

Degree(s):  Title:

Address *(if different from above)*

Street Address:

Street Address 2:

City:  State:  Postal Code:

Country:

Phone:  Fax:

E-mail:

### Other Representative (Optional)

First Name:  MI:  Last Name:

Degree(s):  Title:

Address *(if different from above)*

Street Address:

Street Address 2:

City:  State:  Postal Code:

Country:

Phone:  Fax:

E-mail:

### Other Representative (Optional)

First Name:  MI:  Last Name:

Degree(s):  Title:

Address *(if different from above)*

Street Address:

Street Address 2:

City:  State:  Postal Code:

Country:

Phone:  Fax:

E-mail:

**Please save this form, add your company name to the default document name, and print a copy for your files.  
Then email the printed form to [hesi@hesiglobal.org](mailto:hesi@hesiglobal.org).**

# HESI Committee Mission Statements

## TECHNICAL COMMITTEES

### Application of Genomics to Mechanism-Based Risk Assessment

The mission of the Genomics Technical Committee includes advancing the scientific basis for the development and application of genomic methodologies to mechanism-based risk assessment; addressing scientific issues relating to the use of these technologies as a means for understanding toxic response and mechanisms; and providing a scientific forum for a consensus-based approach to interpreting and applying these data.

### Animal Alternatives in Environmental Risk Assessment

The mission of the Animal Alternatives in Environmental Risk Assessment Technical Committee is to ensure the development of a sound technical basis for alternative tests as a means to reduce, refine, or replace standard ecotoxicity test procedures around the globe. The project aims to provide a forum to coordinate the debates and best emerging practices of the alternatives and animal model development sciences to meet existing hazard assessment, effluent assessment, risk assessment, classification and labeling, and other regulatory needs.

### Cell Therapy - TRacking, Circulation, & Safety (CT-TRACS) Subcommittee

The mission of the Cell Therapy - TRacking, Circulation, & Safety Subcommittee is to establish a collaborative platform where an international network of experts from multiple sectors can share knowledge, experience and resources to facilitate the safe translation of cell based therapies to the clinic, by driving the development of tools, methods and knowledge required to evaluate the *in-vivo* safety and fate of therapeutic cells.

### Development of Methods for a Tiered Approach to Assess the Bioaccumulation of Chemicals

The mission of the Bioaccumulation Technical Committee is to develop the tools needed in a tiered approach for assessing the potential bioaccumulation of organic chemicals.

### Biomarkers of Nephrotoxicity

The mission of the Biomarkers of Nephrotoxicity Technical Committee is to advance the scientific basis for the development and application of biomarkers of target organ toxicity; to develop a systematic approach for the evaluation of biomarkers that bridge from the pre-clinical to clinical stages of drug development; and to provide a scientific forum for building consensus regarding how to apply biomarkers of toxicity in risk assessment. The current focus of this activity is nephrotoxicity.

### Cardiac Safety

The mission of the Cardiac Safety Technical Committee is to develop and disseminate improved data, approaches, and resources for the evaluation of preclinical and clinical cardiac toxicity.

### Developmental and Reproductive Toxicology (DART)

The DART Technical Committee provides a forum where scientists from industry, government and academia can exchange information and initiate activities to advance science related to developmental and reproductive toxicology, and to develop consensus in the scientific community on the appropriate use of experimental toxicity data for human health risk assessment.

### Framework for Intelligent Non-Animal Alternative Methods for Safety Assessment Subcommittee

The mission of the Framework for Intelligent Non-Animal Alternative Methods for Safety Assessment Subcommittee is to establish and bring together the collective knowledge of scientists from academia, industry, and government, towards the development of criteria to establish confidence for using non-animal methods to support regulatory decisions.

### Genetic Toxicology

The mission of the Genetic Toxicology Technical Committee is to improve the scientific basis of the interpretation of results from genetic toxicology tests for purposes of more accurate hazard identification and assessment of human risk. This mission is accomplished by developing follow-up strategies for determining the relevance of test results to human health, building frameworks for integration of test results into a risk-based assessment of the effects of chemical exposures on human health, and by integrating and using new/emerging technologies and scientific knowledge in genetic toxicology hazard and risk assessment.

## **Immunotoxicology**

The mission of the Immunotoxicology Technical Committee is to identify and address scientific issues related to the development and application of immunotoxicology to public health and human health risk assessment; to promote the understanding and appropriate use of immunotoxicologic data to protect human health; and to contribute substantively to the scientific decision-making processes relative to the development of guidelines and regulations for immunotoxicologic testing at the local, national, and international levels.

## **PBPK Project**

The mission of this committee is to identify and address key needs related to PBPK modeling, evaluation, and application practices that could facilitate efficiency in development and consistency in the use of PBPK models in a regulatory context. Initial objectives of this group are to: 1) Develop a standardized PBPK model template and; 2) Develop guidance / a decision tree on PBPK applications based on different degrees of data availability.

## **Protein Allergenicity**

The mission of the HESI Protein Allergenicity Technical Committee (PATC) is to advance the scientific understanding of the relevant parameters defining allergenic proteins, as well as encourage the development of reliable and accurate methodologies for characterizing the allergenic potential of novel proteins.

## **Risk Assessment in the 21st Century**

Officially launched in March 2010, HESI's RISK21 project's multi-stakeholder team members aim to create a systematic approach for incorporating novel approaches and technologies, as available and when appropriate, to aid in advancing human safety assessments. The project is comprised of four overlapping and complementary projects: Exposure Science, Dose-Response, Integrated Evaluation Strategies, and Cumulative Risk.

## **Translational Biomarkers of Neurotoxicity**

The mission of the Translational Biomarkers of Neurotoxicity Committee is to create a comprehensive but practical process for identifying biomarkers associated with the development and expression of neurotoxicity. Current biomarker qualification/validation criteria will be taken into account.

## **EMERGING ISSUES SUBCOMMITTEES**

### **Development of a Tiered Approach for UVCB Ecological Risk Assessment**

The mission of this new EI is to develop a tiered approach to UVCB ecological risk assessment. This group will identify and develop models and methods, develop best practices and guidance, and engage with multi-stakeholder collaborative research projects.

### **Microbiome Biomarkers of Disease and Toxicity**

The mission of this new EI is to determine the data needed to support in vivo, in vitro, ex vivo, and in silico models that integrate the metabolome and microbiome as translational markers of disease and toxicity and determine how the microbiome influences drug safety and chemical toxicity.

**For more information about HESI, write or call:  
ILSI Health and Environmental Sciences Institute  
1156 Fifteenth Street, N.W., Second Floor  
Washington, DC 20005 USA**

**Phone: 202-659-3306; Fax: 202-659-3859  
E-mail: [hesi@hesiglobal.org](mailto:hesi@hesiglobal.org); Web: [www.hesiglobal.org](http://www.hesiglobal.org)**